Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.

Irritable bowel syndrome (IBS) is a chronic digestive condition that causes abdominal pain along with diarrhea, constipation, or both. Many people with IBS also experience bloating and gas. This review examined various treatment options for IBS, including medications and complementary therapies like acupuncture. Researchers found that IBS is a complex condition influenced by multiple factors, including how the gut moves food through the digestive system, heightened sensitivity in the intestines, stress, immune system changes, and gut bacteria imbalances. Because there's no single test to identify what's causing IBS in each person, doctors typically treat the symptoms that bother patients most. The study found that even the most effective treatments only work slightly better than placebo pills, with improvements of just 7-15% over inactive treatments. For constipation-predominant IBS, medications like lubiprostone showed benefits, while for diarrhea-predominant IBS, certain probiotics and antibiotics helped. Some antispasmodic medications and antidepressants can help with abdominal pain. The review noted that complementary and alternative medicine approaches, including probiotics, herbal therapies, and acupuncture, are becoming increasingly popular among IBS patients. However, the authors emphasized that more high-quality research is needed to fully understand how effective and safe these alternative treatments are, and there are concerns about consistent quality standards in manufacturing these products. If you're considering acupuncture for IBS, seek a licensed acupuncturist with experience treating digestive disorders.

This systematic review examined pharmacologic and complementary therapies for irritable bowel syndrome (IBS), a chronic functional gastrointestinal disorder involving abdominal pain and altered bowel habits. The pathophysiology involves altered motility, visceral hypersensitivity, brain-gut dysfunction, immune activation, and microbiome alterations. Without reliable biomarkers, treatment remains symptom-based. Evidence-based therapies for IBS-C include lubiprostone and tegaserod; for IBS-D, Bifidobacter infantis probiotics, rifaximin, and alosetron demonstrated efficacy. Notably, all effective therapies showed only modest therapeutic gain over placebo (7-15%). Selected antispasmodics and antidepressants showed benefits for abdominal pain management. The review acknowledges growing patient interest in complementary and alternative medicine approaches including probiotics, herbal therapies, and acupuncture. However, the authors emphasize significant concerns regarding manufacturing standards and the limited availability of high-quality efficacy and safety data for these modalities. Clinical takeaway: While acupuncture shows promise for IBS management, robust clinical evidence remains limited, warranting cautious integration into treatment protocols pending further research.